Adding Cadonilimab to First-Line Standard Chemotherapy Significantly Improves PFS and OS in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer By Ogkologos - November 15, 2024 428 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the COMPASSION-16 study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR CancerLand Bookshelf : Loosen July 26, 2021 EMA Recommends Granting a Marketing Authorisation for Asciminib July 8, 2022 Nurse Diagnosed with Stage IV Cancer After Thinking Her Pain Was... March 23, 2021 EMA Recommends Extension of Indications for Pembrolizumab to MSI-H or dMMR... April 7, 2022 Load more HOT NEWS FDA Approves Abatacept for Prophylaxis of Acute Graft Versus Host Disease FDA Grants Accelerated Approval to Dostarlimab-gxly for dMMR Advanced Solid Tumours ESMO Issues First Recommendations on Using Next-Generation Sequencing for Advanced Cancers... Zenocutuzumab Approved to Treat Lung and Pancreatic Cancers with Rare Genetic...
